XML 21 R8.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Note 3 - Selected Balance Sheet Data | 6 Months Ended
--- | ---
Dec. 31, 2021
Notes to Financial Statements |
Supplemental Balance Sheet Disclosures [Text Block] | Note 3. Selected Balance Sheet Data: Inventories: Inventories consist of (in thousands):
|  | December 31, |  |  | June 30, |
|  | 2021 |  |  | 2021 |
Raw materials |  | $ | 61,624 |  |  | $ | 55,096 |
Finished goods(1) |  |  | 65,620 |  |  |  | 67,108 |
Inventories, net |  | $ | 127,244 |  |  | $ | 122,204 |
(1)Finished goods inventory of $5,386 and $5,456 included within other long-term assets in the respective December 31, 2021 and June 30, 2021, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date. Property and Equipment: Property and equipment consist of (in thousands):
|  | December 31, |  |  | June 30, |
|  | 2021 |  |  | 2021 |
Land |  | $ | 8,587 |  |  | $ | 8,612 |
Buildings and improvements |  |  | 225,501 |  |  |  | 190,661 |
Machinery and equipment |  |  | 161,431 |  |  |  | 149,410 |
Construction in progress |  |  | 17,386 |  |  |  | 49,073 |
Property and equipment, cost |  |  | 412,905 |  |  |  | 397,756 |
Accumulated depreciation and amortization |  |  | (201,091 | ) |  |  | (189,849 | )
Property and equipment, net |  | $ | 211,814 |  |  | $ | 207,907 |
Intangible Assets: Intangible assets consist of (in thousands):
|  | December 31, |  |  | June 30, |
|  | 2021 |  |  | 2021 |
Developed technology |  | $ | 544,388 |  |  | $ | 552,160 |
Trade names |  |  | 147,327 |  |  |  | 147,640 |
Customer relationships |  |  | 228,419 |  |  |  | 232,493 |
Patents |  |  | 3,116 |  |  |  | 2,926 |
Other intangibles |  |  | 6,309 |  |  |  | 6,316 |
Definite-lived intangible assets |  |  | 929,559 |  |  |  | 941,535 |
Accumulated amortization |  |  | (382,912 | ) |  |  | (348,267 | )
Definite-lived intangibles assets, net |  |  | 546,647 |  |  |  | 593,268 |
In process research and development |  |  | 22,700 |  |  |  | 22,700 |
Total intangible assets, net |  | $ | 569,347 |  |  | $ | 615,968 |
Changes to the carrying amount of net intangible assets for the quarter ended December 31, 2021 consist of (in thousands):
Beginning balance |  | $ | 615,968 |
Acquisitions |  |  | - |
Other additions |  |  | 171 |
Amortization expense |  |  | (37,258 | )
Currency translation |  |  | (971 | )
Eminence impairment (1) |  |  | (8,563 | )
Ending balance |  | $ | 569,347 |
The estimated future amortization expense for intangible assets as of December 31, 2021 is as follows (in thousands):
2022 remainder |  | $ | 36,927 |
2023 |  |  | 71,669 |
2024 |  |  | 68,818 |
2025 |  |  | 65,579 |
2026 |  |  | 61,819 |
Thereafter |  |  | 241,835 |
Total |  | $ | 546,647 |
(1)As disclosed in Note 1, the Company recorded an impairment charge of $8.6 million related to Eminence in Q2 of FY'22. Goodwill: Changes to the carrying amount of goodwill for the quarter ended December 31, 2021 consist of (in thousands):
|  | Protein Sciences |  |  | Diagnostics and Genomics |  |  | Total |
Beginning balance |  | $ | 392,717 |  |  | $ | 450,350 |  |  | $ | 843,067 |
Acquisitions |  |  | - |  |  |  | - |  |  |  | - |
Eminence impairment |  |  | (8,275 | ) |  |  | - |  |  |  | (8,275 | )
Currency translation |  |  | (2,610 | ) |  |  | (126 | ) |  |  | (2,736 | )
Ending balance |  | $ | 381,832 |  |  | $ | 450,224 |  |  | $ | 832,056 |
We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2021. No indicators of impairment were identified as part of our assessment. During the quarter ended September 30, 2021, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment. As disclosed in Note 1, the Company identified a triggering event and a goodwill impairment charge of $8.3 million in the quarter ended December 31, 2021. No additional triggering events or items beyond the upcoming Eminence liquidation were identified during the quarter ended December 31, 2021. The impairment of the Eminence goodwill is the only impairment of goodwill recorded since the adoption of Financial Accounting Standards Board ("FASB") ASC 350 guidance for goodwill and other intangibles on July 1, 2002.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI http://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration